Answers are grounded in this paper and cite their sources.
Although multiple sources for DUR are available in LatAm countries, the accessibility is a major challenge. The procedures for accessing DUR data should be transparent, feasible, affordable, and protocol-driven. This inventory could permit a comparison of drug utilization between countries identifying potential medication-related problems that need further exploration.
No takes yet. Share an insight, caveat, or question.
Lopes et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: